Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/UMEC/VI versus FF/VI in inadequately controlled asthma
NL-OMON45467Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone, umeclidinium and vilanterol in asthma (6 arms), sponsored by GSK. Primary endpoint: Trough FEV1 at Week 24. Started Nov 2016; status: active, not recruiting.
02
Drugs
fluticasoneumeclidiniumvilanterol
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON45467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45467.